author_facet Aleksic, Milos
Liddy, Nathaniel
Molloy, Peter E.
Pumphrey, Nick
Vuidepot, Annelise
Chang, Kyong‐Mi
Jakobsen, Bent K.
Aleksic, Milos
Liddy, Nathaniel
Molloy, Peter E.
Pumphrey, Nick
Vuidepot, Annelise
Chang, Kyong‐Mi
Jakobsen, Bent K.
author Aleksic, Milos
Liddy, Nathaniel
Molloy, Peter E.
Pumphrey, Nick
Vuidepot, Annelise
Chang, Kyong‐Mi
Jakobsen, Bent K.
spellingShingle Aleksic, Milos
Liddy, Nathaniel
Molloy, Peter E.
Pumphrey, Nick
Vuidepot, Annelise
Chang, Kyong‐Mi
Jakobsen, Bent K.
European Journal of Immunology
Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
Immunology
Immunology and Allergy
author_sort aleksic, milos
spelling Aleksic, Milos Liddy, Nathaniel Molloy, Peter E. Pumphrey, Nick Vuidepot, Annelise Chang, Kyong‐Mi Jakobsen, Bent K. 0014-2980 1521-4141 Wiley Immunology Immunology and Allergy http://dx.doi.org/10.1002/eji.201242606 <jats:p><jats:styled-content style="fixed-case">T</jats:styled-content>‐cell destiny during thymic selection depends on the affinity of the <jats:styled-content style="fixed-case">TCR</jats:styled-content> for autologous peptide ligands presented in the context of <jats:styled-content style="fixed-case">MHC</jats:styled-content> molecules. This is a delicately balanced process; robust binding leads to negative selection, yet some affinity for the antigen complex is required for positive selection. All <jats:styled-content style="fixed-case">TCR</jats:styled-content>s of the resulting repertoire thus have some intrinsic affinity for an <jats:styled-content style="fixed-case">MHC</jats:styled-content> type presenting an assortment of peptides. Generally, <jats:styled-content style="fixed-case">TCR</jats:styled-content> affinities of peripheral <jats:styled-content style="fixed-case">T</jats:styled-content> cells will be low toward self‐derived peptides, as these would have been presented during thymic selection, whereas, by serendipity, binding to pathogen‐derived peptides that are encountered de novo could be stronger. A crucial question in assessing immunotherapeutic strategies for cancer is whether natural <jats:styled-content style="fixed-case">TCR</jats:styled-content> repertoires have the capacity for efficiently recognizing tumor‐associated peptide antigens. Here, we report a comprehensive comparison of <jats:styled-content style="fixed-case">TCR</jats:styled-content> affinities to a range of <jats:styled-content style="fixed-case">HLA</jats:styled-content>‐<jats:styled-content style="fixed-case">A</jats:styled-content>2 presented antigens. <jats:styled-content style="fixed-case">TCR</jats:styled-content>s that bind viral antigens fall within a strikingly higher affinity range than those that bind cancer‐related antigens. This difference may be one of the key explanations for tumor immune escape and for the deficiencies of <jats:styled-content style="fixed-case">T</jats:styled-content>‐cell vaccines against cancer.</jats:p> Different affinity windows for virus and cancer‐specific <scp>T</scp>‐cell receptors: Implications for therapeutic strategies European Journal of Immunology
doi_str_mv 10.1002/eji.201242606
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9lamkuMjAxMjQyNjA2
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9lamkuMjAxMjQyNjA2
institution DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
imprint Wiley, 2012
imprint_str_mv Wiley, 2012
issn 0014-2980
1521-4141
issn_str_mv 0014-2980
1521-4141
language English
mega_collection Wiley (CrossRef)
match_str aleksic2012differentaffinitywindowsforvirusandcancerspecifictcellreceptorsimplicationsfortherapeuticstrategies
publishDateSort 2012
publisher Wiley
recordtype ai
record_format ai
series European Journal of Immunology
source_id 49
title Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_unstemmed Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_full Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_fullStr Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_full_unstemmed Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_short Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_sort different affinity windows for virus and cancer‐specific <scp>t</scp>‐cell receptors: implications for therapeutic strategies
topic Immunology
Immunology and Allergy
url http://dx.doi.org/10.1002/eji.201242606
publishDate 2012
physical 3174-3179
description <jats:p><jats:styled-content style="fixed-case">T</jats:styled-content>‐cell destiny during thymic selection depends on the affinity of the <jats:styled-content style="fixed-case">TCR</jats:styled-content> for autologous peptide ligands presented in the context of <jats:styled-content style="fixed-case">MHC</jats:styled-content> molecules. This is a delicately balanced process; robust binding leads to negative selection, yet some affinity for the antigen complex is required for positive selection. All <jats:styled-content style="fixed-case">TCR</jats:styled-content>s of the resulting repertoire thus have some intrinsic affinity for an <jats:styled-content style="fixed-case">MHC</jats:styled-content> type presenting an assortment of peptides. Generally, <jats:styled-content style="fixed-case">TCR</jats:styled-content> affinities of peripheral <jats:styled-content style="fixed-case">T</jats:styled-content> cells will be low toward self‐derived peptides, as these would have been presented during thymic selection, whereas, by serendipity, binding to pathogen‐derived peptides that are encountered de novo could be stronger. A crucial question in assessing immunotherapeutic strategies for cancer is whether natural <jats:styled-content style="fixed-case">TCR</jats:styled-content> repertoires have the capacity for efficiently recognizing tumor‐associated peptide antigens. Here, we report a comprehensive comparison of <jats:styled-content style="fixed-case">TCR</jats:styled-content> affinities to a range of <jats:styled-content style="fixed-case">HLA</jats:styled-content>‐<jats:styled-content style="fixed-case">A</jats:styled-content>2 presented antigens. <jats:styled-content style="fixed-case">TCR</jats:styled-content>s that bind viral antigens fall within a strikingly higher affinity range than those that bind cancer‐related antigens. This difference may be one of the key explanations for tumor immune escape and for the deficiencies of <jats:styled-content style="fixed-case">T</jats:styled-content>‐cell vaccines against cancer.</jats:p>
container_issue 12
container_start_page 3174
container_title European Journal of Immunology
container_volume 42
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792346892428902407
geogr_code not assigned
last_indexed 2024-03-01T17:46:37.332Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Different+affinity+windows+for+virus+and+cancer%E2%80%90specific+T%E2%80%90cell+receptors%3A+Implications+for+therapeutic+strategies&rft.date=2012-12-01&genre=article&issn=1521-4141&volume=42&issue=12&spage=3174&epage=3179&pages=3174-3179&jtitle=European+Journal+of+Immunology&atitle=Different+affinity+windows+for+virus+and+cancer%E2%80%90specific+%3Cscp%3ET%3C%2Fscp%3E%E2%80%90cell+receptors%3A+Implications+for+therapeutic+strategies&aulast=Jakobsen&aufirst=Bent+K.&rft_id=info%3Adoi%2F10.1002%2Feji.201242606&rft.language%5B0%5D=eng
SOLR
_version_ 1792346892428902407
author Aleksic, Milos, Liddy, Nathaniel, Molloy, Peter E., Pumphrey, Nick, Vuidepot, Annelise, Chang, Kyong‐Mi, Jakobsen, Bent K.
author_facet Aleksic, Milos, Liddy, Nathaniel, Molloy, Peter E., Pumphrey, Nick, Vuidepot, Annelise, Chang, Kyong‐Mi, Jakobsen, Bent K., Aleksic, Milos, Liddy, Nathaniel, Molloy, Peter E., Pumphrey, Nick, Vuidepot, Annelise, Chang, Kyong‐Mi, Jakobsen, Bent K.
author_sort aleksic, milos
container_issue 12
container_start_page 3174
container_title European Journal of Immunology
container_volume 42
description <jats:p><jats:styled-content style="fixed-case">T</jats:styled-content>‐cell destiny during thymic selection depends on the affinity of the <jats:styled-content style="fixed-case">TCR</jats:styled-content> for autologous peptide ligands presented in the context of <jats:styled-content style="fixed-case">MHC</jats:styled-content> molecules. This is a delicately balanced process; robust binding leads to negative selection, yet some affinity for the antigen complex is required for positive selection. All <jats:styled-content style="fixed-case">TCR</jats:styled-content>s of the resulting repertoire thus have some intrinsic affinity for an <jats:styled-content style="fixed-case">MHC</jats:styled-content> type presenting an assortment of peptides. Generally, <jats:styled-content style="fixed-case">TCR</jats:styled-content> affinities of peripheral <jats:styled-content style="fixed-case">T</jats:styled-content> cells will be low toward self‐derived peptides, as these would have been presented during thymic selection, whereas, by serendipity, binding to pathogen‐derived peptides that are encountered de novo could be stronger. A crucial question in assessing immunotherapeutic strategies for cancer is whether natural <jats:styled-content style="fixed-case">TCR</jats:styled-content> repertoires have the capacity for efficiently recognizing tumor‐associated peptide antigens. Here, we report a comprehensive comparison of <jats:styled-content style="fixed-case">TCR</jats:styled-content> affinities to a range of <jats:styled-content style="fixed-case">HLA</jats:styled-content>‐<jats:styled-content style="fixed-case">A</jats:styled-content>2 presented antigens. <jats:styled-content style="fixed-case">TCR</jats:styled-content>s that bind viral antigens fall within a strikingly higher affinity range than those that bind cancer‐related antigens. This difference may be one of the key explanations for tumor immune escape and for the deficiencies of <jats:styled-content style="fixed-case">T</jats:styled-content>‐cell vaccines against cancer.</jats:p>
doi_str_mv 10.1002/eji.201242606
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9lamkuMjAxMjQyNjA2
imprint Wiley, 2012
imprint_str_mv Wiley, 2012
institution DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4
issn 0014-2980, 1521-4141
issn_str_mv 0014-2980, 1521-4141
language English
last_indexed 2024-03-01T17:46:37.332Z
match_str aleksic2012differentaffinitywindowsforvirusandcancerspecifictcellreceptorsimplicationsfortherapeuticstrategies
mega_collection Wiley (CrossRef)
physical 3174-3179
publishDate 2012
publishDateSort 2012
publisher Wiley
record_format ai
recordtype ai
series European Journal of Immunology
source_id 49
spelling Aleksic, Milos Liddy, Nathaniel Molloy, Peter E. Pumphrey, Nick Vuidepot, Annelise Chang, Kyong‐Mi Jakobsen, Bent K. 0014-2980 1521-4141 Wiley Immunology Immunology and Allergy http://dx.doi.org/10.1002/eji.201242606 <jats:p><jats:styled-content style="fixed-case">T</jats:styled-content>‐cell destiny during thymic selection depends on the affinity of the <jats:styled-content style="fixed-case">TCR</jats:styled-content> for autologous peptide ligands presented in the context of <jats:styled-content style="fixed-case">MHC</jats:styled-content> molecules. This is a delicately balanced process; robust binding leads to negative selection, yet some affinity for the antigen complex is required for positive selection. All <jats:styled-content style="fixed-case">TCR</jats:styled-content>s of the resulting repertoire thus have some intrinsic affinity for an <jats:styled-content style="fixed-case">MHC</jats:styled-content> type presenting an assortment of peptides. Generally, <jats:styled-content style="fixed-case">TCR</jats:styled-content> affinities of peripheral <jats:styled-content style="fixed-case">T</jats:styled-content> cells will be low toward self‐derived peptides, as these would have been presented during thymic selection, whereas, by serendipity, binding to pathogen‐derived peptides that are encountered de novo could be stronger. A crucial question in assessing immunotherapeutic strategies for cancer is whether natural <jats:styled-content style="fixed-case">TCR</jats:styled-content> repertoires have the capacity for efficiently recognizing tumor‐associated peptide antigens. Here, we report a comprehensive comparison of <jats:styled-content style="fixed-case">TCR</jats:styled-content> affinities to a range of <jats:styled-content style="fixed-case">HLA</jats:styled-content>‐<jats:styled-content style="fixed-case">A</jats:styled-content>2 presented antigens. <jats:styled-content style="fixed-case">TCR</jats:styled-content>s that bind viral antigens fall within a strikingly higher affinity range than those that bind cancer‐related antigens. This difference may be one of the key explanations for tumor immune escape and for the deficiencies of <jats:styled-content style="fixed-case">T</jats:styled-content>‐cell vaccines against cancer.</jats:p> Different affinity windows for virus and cancer‐specific <scp>T</scp>‐cell receptors: Implications for therapeutic strategies European Journal of Immunology
spellingShingle Aleksic, Milos, Liddy, Nathaniel, Molloy, Peter E., Pumphrey, Nick, Vuidepot, Annelise, Chang, Kyong‐Mi, Jakobsen, Bent K., European Journal of Immunology, Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies, Immunology, Immunology and Allergy
title Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_full Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_fullStr Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_full_unstemmed Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_short Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
title_sort different affinity windows for virus and cancer‐specific <scp>t</scp>‐cell receptors: implications for therapeutic strategies
title_unstemmed Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategies
topic Immunology, Immunology and Allergy
url http://dx.doi.org/10.1002/eji.201242606